CCND1

MILAN--(BUSINESS WIRE)-- Sibylla Biotech today announces the appointment of Sonia Poli, Ph.D., as Chief Scientific Officer (CSO). Dr. Poli brings more than two decades of international experience in pharmaceutical research and development, with broad knowledge spanning small molecule drug design, translational science, and early- to late-stage clinical development. As a seasoned pharmaceutical R&D executive, Dr. Poli has held various leadership and executive positions at both large and small pharmaceutical companies across disciplines and indications. Dr. Poli will guide the scientific direction and strategy at Sibylla as the company advances its proprietary pipeline of small molecule Folding Interfering Degraders (FIDs) to address a range of therapeutic areas. "Sonia’s profound expertise in clinical development, coupled with her extensive knowledge of small molecule drug design, align seamlessly with the goal of advancing our FIDs toward the clinic, starting with our lead asset – a Cyclin D1 degrader," stated Lidia Pieri, Co-Founder and Chief Executive Officer of Sibylla Biotech. "Welcoming Sonia to our leadership team as CSO not only strengthens our team but also amplifies Sibylla’s capacity to unlock the promise of our PPI-FIT protein folding simulation technology to address currently undruggable targets across indications." "Sibylla’s pioneering approach to rational drug discovery is distinct, not only because of its focus on targeting proteins during their folding process but also due to the team’s unique constellation of physicists and biologists. This blend of expertise has already generated and validated several compounds that act on proteins of oncological interest," said Dr. Sonia Poli, CSO of Sibylla Biotech. "Working as part of the Sibylla team presents a tremendous opportunity to contribute to the company’s computational protein folding platform and create truly transformative treatment options in areas of high unmet need." Dr. Sonia Poli is a pharmaceutical industry veteran with profound drug development knowledge. For the past three years, Dr. Poli has served as Life Cycle Leader for AC Immune’s partnership with Eli Lilly on the Tau morphomer program. Prior to this, Dr. Poli was the CSO of Minoryx and Vice President of Translational Science of AC Immune and has been a Board member of Dimerix Bioscience since 2013. Her earlier tenure at Addex Therapeutics spanned over a decade, during which she ascended to various leadership positions, culminating in the role of CSO. Before her time at Addex Therapeutics, she dedicated seven years to Roche, working in roles of increasing responsibility. Dr. Poli’s professional journey commenced with a post-doctoral research stint at CNRS URA400, Université René Descartes, Paris V, after obtaining her Ph.D. in Industrial Chemistry from Università degli Studi di Milano. About Sibylla Biotech Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein. Through its protein folding simulation technology platform, Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. For further information: View source version on businesswire.com: Contacts Sibylla Biotech Lidia Pieri +39 347 6499534 lidia.pieri@sibyllabiotech.it Trophic Communications Valeria Fisher or Dr. Alison Opalko +49 175 80 41 816 or +49 151 54041130 sibylla@trophic.eu Source: Sibylla Biotech View this news release online at:

MILAN--(BUSINESS WIRE)-- Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors. Dr. Bridon brings more than 30 years of experience in operations as well as research and development in the pharmaceutical and biotechnology sectors. As an expert in implementing AI-based technologies for drug development and with a broad knowledge base in precision oncology, Dr. Bridon has successfully led drug discovery efforts from conception to clinical development. Joining Sibylla, Dr. Bridon will contribute his expertise and lead the Board as Sibylla expands its proprietary pipeline of innovative protein degraders. “Dominique’s background in advancing new therapeutics, his proven track record as a successful biotech entrepreneur and his passion for science that is a great fit for Sibylla’s culture will be highly valuable as we enter the next stages of our corporate growth,” commented Lidia Pieri, Co-Founder and Chief Executive Officer of Sibylla Biotech. “We are leveraging our protein folding simulation platform to build out our pipeline starting with our lead candidate designed to degrade Cyclin D1, a protein that is amplified and overexpressed in a range of cancers but remains elusive to drug targeting efforts. During this period of progressive expansion in our preclinical activities, Dominique's engagement will be instrumental.” “Sibylla Biotech’s cutting-edge PPI-FIT technology has the potential to address previously undruggable targets across many indications and redefine the protein degradation landscape,” said Dr. Dominique Bridon. “I look forward to working with the team and the Board to continue advancing Sibylla’s highly-differentiated approach while driving the further development of its lead candidate in oncology.” Dr. Dominique Bridon has served as CEO of Diaccurate SAS, a clinical-stage biopharmaceutical company developing precision oncology therapies, since 2020. Prior to this, Dr. Bridon held a range of senior positions at various pharmaceutical and biotechnology companies, including Senior Vice President and acting CSO, Discovery and Innovation at Ipsen, a leader in peptide and protein therapeutics. Dr. Bridon is the scientific co-founder of several biotechnology companies and is an inventor and co-inventor of more than 50 patents and patent applications. He is also a member of the Scientific Boards of Jalon Therapeutics, Concarlo Therapeutics, and EpiVax Therapeutics. Dr. Bridon holds a Ph.D. in Organic Chemistry from the University of Paris XI and completed a post-doctoral research position at the University of California, Berkeley. He obtained an M.S. in Chemical Engineering from the École Nationale Supérieure de Chimie and an M.S. in Polymer Sciences from the University of Clermont-Ferrand. About Sibylla Biotech Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein. Through its protein folding simulation technology platform, Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. For further information: View source version on businesswire.com: Contacts Sibylla Biotech Lidia Pieri +39 347 6499534 lidia.pieri@sibyllabiotech.it Trophic Communications Valeria Fisher or Dr. Alison Opalko +49 175 80 41 816 or +49 151 54041130 sibylla@trophic.eu Source: Sibylla Biotech View this news release online at:

In a pre-clinical, proof-of-concept study, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be promising for both treating and preventing uterine fibroids. Results of the study add to growing evidence that EGCG may reduce fibroid cell growth. The study was specifically designed to identify the biochemical mechanisms responsible for EGCG action in fibroid cells. In a pre-clinical, proof-of-concept study from Johns Hopkins Medicine, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be promising for both treating and preventing uterine fibroids. Results of the study, first posted online May 25 in Scientific Reports, add to growing evidence that EGCG may reduce fibroid cell growth. The study was specifically designed to identify the biochemical mechanisms responsible for EGCG action in fibroid cells. The investigators emphasize that their study involves human fibroid cells grown in the laboratory and treated with EGCG extract to explore the possibility of oral EGCG supplementation as a therapy, rather than just drinking cups of green tea as a preventative measure for uterine fibroids. "The purpose of this study was to examine how EGCG works to treat and prevent uterine fibroids," says James Segars Jr., M.D., professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. "There is no standard protocol for uterine fibroid disease management or prevention, no tools to prevent their growth, so finding a safe nonsurgical therapy is important." Uterine fibroids are the most common benign tumors of the uterus. Made up of smooth muscle cells and a large matrix of connective tissue, the fibroids range in size from nearly microscopic to bulky masses that can enlarge and distort the uterus. An estimated 77% of women will develop fibroids in their lifetime, most of them by age 50. Black and Hispanic women develop them at 1.5 to two times the rate of white women. While many people with uterine fibroids are without symptoms, about 25% experience significant symptoms including heavy uterine bleeding, pelvic pain and infertility. Uterine fibroids are the leading cause of hospitalizationhysterectomy in the United States, according to the U.S. Department of Health and Human Services. In addition to complete removal of the uterus, surgical treatment may include various means of removing fibroid tumors from the uterine wall. For the new study, researchers used laboratory cultures of uterine fibroids collected from living patients. Because uterine fibroid cells have a large extracellular matrix (the network of macromolecules and minerals in tissues that support, but are not part of, cells) compared to normal cells, researchers designed their experiments to see if treatment of cells with EGCG affects protein expression associated with this matrix. Specifically, they studied fibronectin, a matrix protein; cyclin D1, a protein involved with cell division; and connective tissue growth factor (CTGF) protein. Cells were dosed with 100 micromoles (a micromole is 1 millionth of a mole) per liter of EGCG in growth media for 24 hours, and then a Western blot -- a laboratory technique used to detect a specific protein in a blood or tissue sample -- was performed. In this study, researchers looked for levels of cyclin D1 and CTGF proteins in EGCG-treated fibroid cells compared to untreated cell. They found that EGCG reduced protein levels of fibronectin by 46% to 52%, compared with an untreated control group of fibroid cells. They also found that EGCG disrupted pathways involved in fibroid tumor cell growth, movement, signaling and metabolism, and they saw up to an 86% decrease in CTGF proteins compared with the control group. "The results from this study show that EGCG targets many signaling pathways involved in fibroid growth, particularly the extracellular matrix," says study lead author Md Soriful Islam, Ph.D., M.Sc., a postdoctoral fellow at the Johns Hopkins University School of Medicine. "EGCG supplements could be an easily accessible and natural way to relieve symptoms and slow fibroid growth." These results lend support to the FRIEND (Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural Compound in Green Tea) study (ClinicalTrials.gov identifier NCT05364008), an ongoing clinical trial of EGCG in women with fibroids who are seeking pregnancy. While results from this study show promise, researchers caution that more studies need to be done, and consumers should not try to self-dose with green tea supplements. Future research on EGCG will include clinical trials with large and diverse patient groups to determine optimal doses as well as possible side effects of EGCG supplementation. Other scientists at the Johns Hopkins University School of Medicine who contributed to this research are Maclaine Parish, Joshua Brennan and Briana Winer. Segars has been a primary investigator on research sponsored by Bayer, Abbvie, BioSpecifics Technologies Corp., Allergan and Myovant Sciences. All other authors have no conflicts to disclose. This research was partly supported by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Howard W. and Georgeanna Seegar Jones Endowment.